The Effects of GSK2586881 on the Responses to Acute Hypoxia and Exercise
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2017
At a glance
- Drugs GSK 2586881 (Primary)
- Indications Acute lung injury; Respiratory distress syndrome
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 19 Jun 2017 Planned End Date changed from 18 Dec 2017 to 21 Dec 2017.
- 19 Jun 2017 Planned primary completion date changed from 18 Dec 2017 to 21 Dec 2017.
- 19 Jun 2017 Status changed from not yet recruiting to recruiting.